With 37 million people living with HIV worldwide, and over 2 million new infections diagnosed each year, an effective vaccine is regarded as the most potent public health strategy for addressing the pandemic. Despite the many advances in the understanding, treatment and prevention of HIV made over the past 30 years, the development of broadly-effective HIV vaccine has remained unachievable.
The European HIV Alliance (EHVA) is a five year project funded by the European Union’s Horizon 2020 Research and Innovation Programme designed to foster the development of an effective vaccine. The EHVA encompasses 39 partners, each with the expertise to promote a comprehensive approach to the development of an effective HIV vaccine. The international alliance, which includes academic and industrial research partners from all over Europe, as well as sub-Saharan Africa and North America, will work to discover and progress novel vaccine candidates through the clinic.
The European HIV Vaccine Alliance (EHVA) announces the start of the EHVA T01 / ANRS VRI05 trial, with the initiation of screening of participants at the Lausanne University Hospital Switzerland.
Drawing from 39 partner organizations, EHVA encompasses expertise in the fields of molecular biology, structural biology, vectorology, adjuvants delivery, immunology, clinical science and biostatics. The alliance is devised to approach the challenges that have hindered the development of a broadly effective vaccine, to date, from all possible angles.
The multidisciplinary-partnership alliance was initiated by Professor Yves Levy of the French Institute of Health (INSERM) and Professor Giuseppe Pantaleo of the Swiss Vaccine Research Institute...
EHVA fosters a multidisciplinary approach to the challenge of developing broadly effective HIV vaccines.
EHVA’s programme primary goals are to:
This project has received funding from the European Union's Horizon 2020 research